logo

Catalyst Pharmaceutical Partners Inc. (CPRX)



Trade CPRX now with
  Date
  Headline
5/29/2018 8:05:39 AM Catalyst : FDA Accepts NDA And Priority Review Status For Firdapse For Lambert-Eaton Myasthenic Syndrome
4/19/2018 8:03:42 AM Catalyst Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In MuSK Antibody Positive Myasthenia Gravis
3/29/2018 8:20:33 AM Catalyst Announces Submission Of NDA For Firdapse For Treatment Of Lambert-Eaton Myasthenic Syndrome
2/12/2018 8:06:10 AM Catalyst Pharmaceuticals Plans To Resubmit NDA For Firdapse On Schedule For End Of Q1